TCGA cohort (n = 79) | Univariate | Multivariate | ||||||
---|---|---|---|---|---|---|---|---|
Variable | EFS HR (95% CI) | EFS p.value | OS HR (95% CI) | OS p.value | EFS HR (95% CI) | EFS p.value | OS HR (95% CI) | OS p.value |
Age > 60 | 1.93 (1.18–3.17) | 0.009*** | 2.24 (1.32–3.81) | 0.003*** | 1.45 (0.846–2.47) | 0.178 | 1.58 (0.883–2.82) | 0.124 |
BM blast > 70% | 1.54 (0.804–2.96) | 0.192 | 1.48 (0.747–2.94) | 0.260 |  |  |  |  |
CD69+ HSC-like% (high vs low) | 2.47 (1.5–4.07) | 0.000*** | 2.36 (1.39–4.02) | 0.001*** | 1.85 (1.04–3.27) | 0.035** | 2.1 (1.17–3.76) | 0.013** |
LSC score (high vs low) | 2.87 (1.72–4.81) | 0.000*** | 2.47 (1.44–4.23) | 0.001*** | 2.5 (1.34–4.66) | 0.004*** | 2.11 (1.12–3.98) | 0.021** |
Gender (male vs female) | 0.988 (0.604–1.62) | 0.962 | 0.943 (0.56–1.59) | 0.824 |  |  |  |  |
Cytogenetic Risk Favorable | 0.606 (0.261–1.41) | 0.243 | 0.514 (0.205–1.29) | 0.157 |  |  |  |  |
Cytogenetic Risk Intermediate/Normal | 1.1 (0.648–1.88) | 0.719 | 1.22 (0.689–2.16) | 0.495 |  |  |  |  |
Cytogenetic Risk Poor | 1.21 (0.668–2.2) | 0.529 | 1.18 (0.624–2.25) | 0.606 |  |  |  |  |
Molecular Risk Good | 0.606 (0.261–1.41) | 0.243 | 0.514 (0.205–1.29) | 0.157 |  |  |  |  |
Molecular Risk Intermediate | 0.958 (0.575–1.6) | 0.870 | 0.833 (0.486–1.43) | 0.504 |  |  |  |  |
Molecular Risk Poor | 1.39 (0.806–2.41) | 0.234 | 1.87 (1.05–3.33) | 0.033** | 1.13 (0.625–2.04) | 0.689 | 1.88 (1.01–3.47) | 0.045** |
cytogenetic BCR-ABL1 | 12.9 (2.75–60.1) | 0.001*** | 1.73 (0.237–12.7) | 0.588 |  |  |  |  |
cytogenetic CBFB-MYH11 | 0.847 (0.307–2.34) | 0.749 | 0.603 (0.188–1.94) | 0.395 |  |  |  |  |
cytogenetic Complex | 1.1 (0.439–2.74) | 0.844 | 1.6 (0.636–4.02) | 0.318 |  |  |  |  |
cytogenetic Intermediate Risk Abnormality | 1.56 (0.788–3.1) | 0.201 | 1.52 (0.741–3.13) | 0.252 |  |  |  |  |
cytogenetic MLL, poor risk | 0.826 (0.202–3.38) | 0.791 | 1.03 (0.25–4.23) | 0.969 |  |  |  |  |
cytogenetic MLL, t(9;11) | 2.55 (0.345–18.8) | 0.360 | 4.01 (0.533–30.1) | 0.177 |  |  |  |  |
cytogenetic Normal | 0.843 (0.514–1.38) | 0.497 | 0.798 (0.471–1.35) | 0.399 |  |  |  |  |
cytogenetic Poor Risk Abnormality | 1.13 (0.407–3.11) | 0.819 | 1.57 (0.564–4.34) | 0.389 |  |  |  |  |
cytogenetic RUNX1-RUNX1T1 | 0.41 (0.1–1.68) | 0.215 | 0.463 (0.113–1.9) | 0.285 |  |  |  |  |
FLT3-ITD | 1.41 (0.828–2.4) | 0.206 | 1.12 (0.628–2.01) | 0.693 |  |  |  |  |
FLT3-PM | 2.05 (0.929–4.53) | 0.075* | 2.71 (1.2–6.08) | 0.016** |  |  |  |  |
CEBPA mutation | 0.663 (0.241–1.83) | 0.427 | 0.708 (0.256–1.96) | 0.507 |  |  |  |  |
DNMT3A/B mutation | 1.54 (0.898–2.64) | 0.117 | 2.13 (1.22–3.74) | 0.008*** |  |  |  |  |
NPM1 mutation | 0.839 (0.503–1.4) | 0.502 | 0.765 (0.443–1.32) | 0.336 |  |  |  |  |
RUNX1 mutation | 1.39 (0.552–3.51) | 0.484 | 1.89 (0.742–4.84) | 0.181 |  |  |  |  |
TP53 mutation | 2.34 (0.846–6.47) | 0.101 | 3.62 (1.29–10.2) | 0.015** |  |  |  |  |
WT1 mutation | 0.988 (0.45–2.17) | 0.977 | 0.733 (0.314–1.71) | 0.474 |  |  |  |  |
SCT | 0.642 (0.392–1.05) | 0.078* | 0.483 (0.284–0.822) | 0.007*** | 0.497 (0.282–0.874) | 0.015** | 0.353 (0.19–0.657) | 0.001*** |